Evidence map›Paper›PMID 39244036›Full record

ArticleClinical medicine (London, England)2024

Utilising accessible and reproducible neurological assessments in clinical studies: Insights from use of the Neurological Impairment Scale in the multi-centre COVID-CNS study.

Ali M Alam, Glynn W Webb, Ceryce Collie, Sashini Mariathasan, Yun Huang, Orla Hilton, Rajish Shil, Katherine C Dodd, James B Lilleker, Craig J Smith and 16 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical medicine (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Ali M AlamInfection Neuroscience Laboratory, Institute of Infection, Veterinary and Ecological Science, University of Liverpool, NIHR HPRU for Emerging and Zoonotic Infection, Liverpool, UK.
Glynn W WebbInfection Neuroscience Laboratory, Institute of Infection, Veterinary and Ecological Science, University of Liverpool, NIHR HPRU for Emerging and Zoonotic Infection, Liverpool, UK.
Ceryce CollieInfection Neuroscience Laboratory, Institute of Infection, Veterinary and Ecological Science, University of Liverpool, NIHR HPRU for Emerging and Zoonotic Infection, Liverpool, UK.
Sashini MariathasanNational Hospital for Neurology and Neurosurgery, London, UK.
Yun HuangInfection Neuroscience Laboratory, Institute of Infection, Veterinary and Ecological Science, University of Liverpool, NIHR HPRU for Emerging and Zoonotic Infection, Liverpool, UK.
Orla HiltonInfection Neuroscience Laboratory, Institute of Infection, Veterinary and Ecological Science, University of Liverpool, NIHR HPRU for Emerging and Zoonotic Infection, Liverpool, UK.
Rajish ShilInfection Neuroscience Laboratory, Institute of Infection, Veterinary and Ecological Science, University of Liverpool, NIHR HPRU for Emerging and Zoonotic Infection, Liverpool, UK.
Katherine C DoddManchester Centre for Clinical Neurosciences, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Salford, UK.
James B LillekerManchester Centre for Clinical Neurosciences, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Salford, UK.
Craig J SmithManchester Centre for Clinical Neurosciences, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Salford, UK; Divsion of Cardiovascular Sciences, University of Manchester, Manchester, UK.
Ava EastonInfection Neuroscience Laboratory, Institute of Infection, Veterinary and Ecological Science, University of Liverpool, NIHR HPRU for Emerging and Zoonotic Infection, Liverpool, UK; Encephalitis International, Malton, UK.
Arina TamborskaInfection Neuroscience Laboratory, Institute of Infection, Veterinary and Ecological Science, University of Liverpool, NIHR HPRU for Emerging and Zoonotic Infection, Liverpool, UK.
Rhys H ThomasTranslational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
Nicholas W S DaviesDepartment of Neurology, Charing Cross Hospital, London, UK.
Thomas M JenkinsSheffield Institute for Translational Neuroscience, University of Sheffield, UK; Curtin University, Perth, Western Australia.
Michael ZandiNational Hospital for Neurology and Neurosurgery, London, UK.
Laura BenjaminNational Hospital for Neurology and Neurosurgery, London, UK.
Mark A EllulInfection Neuroscience Laboratory, Institute of Infection, Veterinary and Ecological Science, University of Liverpool, NIHR HPRU for Emerging and Zoonotic Infection, Liverpool, UK.
Tom SolomonInfection Neuroscience Laboratory, Institute of Infection, Veterinary and Ecological Science, University of Liverpool, NIHR HPRU for Emerging and Zoonotic Infection, Liverpool, UK; The Pandemic Institute, Liverpool, UK.
Thomas A PollakDepartment of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Tim NicholsonSection of Cognitive Neuropsychiatry, Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Gerome BreenInstitute of Psychiatry, Psychology & Neuroscience; Social, Genetic & Developmental Psychiatry Centre, King's College London, London, UK.
Daniel J van WamelenInstitute of Psychiatry, Psychology & Neuroscience, Department of Neuroimaging, King's College London, London, UK.
Nicholas W WoodDepartment of Clinical and Movement Neurosciences, University College London, UCL Queen Square Institute of Neurology, London, UK.
Benedict D MichaelInfection Neuroscience Laboratory, Institute of Infection, Veterinary and Ecological Science, University of Liverpool, NIHR HPRU for Emerging and Zoonotic Infection, Liverpool, UK. Electronic address: benmic@liverpool.ac.uk.
(on Behalf of the COVID-CNS Group)Infection Neuroscience Laboratory, Institute of Infection, Veterinary and Ecological Science, University of Liverpool, NIHR HPRU for Emerging and Zoonotic Infection, Liverpool, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Reproducible and standardised neurological assessment scales are important in quantifying research outcomes. These scales are often performed by non-neurologists and/or non-clinicians and must be robust, quantifiable, reproducible and comparable to a neurologist's assessment. COVID-CNS is a multi-centre study which utilised the Neurological Impairment Scale (NIS) as a core assessment tool in studying neurological outcomes following COVID-19 infection. We investigated the strengths and weaknesses of the NIS when used by non-neurology clinicians and non-clinicians, and compared performance to a structured neurological examination performed by a neurology clinician. Through our findings, we provide practical advice on how non-clinicians can be readily trained in conducting reproducible and standardised neurological assessments in a multi-centre study, as well as illustrating potential pitfalls of these tools.

Indexed as

COVID-19Nervous System DiseasesNeurologic ExaminationHumansReproducibility of ResultsSARS-CoV-2Severity of Illness IndexClinical studyCOVID-19Neurological assessmentNeurologyOutcome tool

Identifiers

PMID39244036
PMCPMC11420440

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.